What pharma/med tech firms should know about interacting with healthcare professionals in the US

On 10 July 2008, the Pharmaceutical Research and Manufacturers of America (PhRMA) revised its Code on Interactions with Healthcare Professionals (Code). The revised Code will take effect in January 2009. Compliance with the Code is generally voluntary, however, in a growing trend, two states have incorporated the Code into laws addressing interactions with healthcare professionals. Under California Health & Safety Code § 119402, certain pharmaceutical and medical device companies doing business in California must create comprehensive compliance programs that are consistent with PhRMA’s revised Code.

On 10 July 2008, the Pharmaceutical Research and Manufacturers of America (PhRMA) revised its Code on Interactions with Healthcare Professionals (Code). The revised Code will take effect in January 2009. Compliance with the Code is generally voluntary, however, in a growing trend, two states have incorporated the Code into laws addressing interactions with healthcare professionals. Under California Health & Safety Code § 119402, certain pharmaceutical and medical device companies doing business in California must create comprehensive compliance programs that are consistent with PhRMA’s revised Code.

And, under a recently passed and more aggressive law, the commonwealth of Massachusetts has mandated that its Department of Public Health adopt a standard marketing code of conduct for all...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By 

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By 

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.